ARCADIA BIOSCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.01 USD | +0.75% |
|
-1.95% | -35.78% |
| Mar. 28 | Arcadia Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Mar. 28 | Transcript : Arcadia Biosciences, Inc., Q4 2023 Earnings Call, Mar 28, 2024 |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
Ratings chart - Surperformance
Sector: Agricultural Chemicals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -35.78% | 2.74M | - | ||
| +20.03% | 40.09B | C | ||
| -.--% | 11.23B | - | B+ | |
| +5.87% | 8.33B | A | ||
| -0.11% | 6.38B | B- | ||
| -0.11% | 6.36B | B+ | ||
| -2.06% | 5.85B | B | ||
| +38.21% | 5.48B | B- | ||
| -15.62% | 5.29B | - | C- | |
| -18.60% | 4.27B | C+ |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- RKDA Stock
- Ratings Arcadia Biosciences, Inc.